Author: alcyon

Hedi Ben Brahim

  Director Hedi Ben Brahim has been Chairman and CEO, and CEO of Transgene from 2021 to 2023. Hedi Ben Brahim joined the Company from Institut Mérieux where he was Vice-President for Immunotherapy since 2018. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO).… Continue reading Hedi Ben Brahim

innovation box

Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our myvac® platform Discover our invir.IO® platform

TG4001 box

TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers.   More information

myvac-box

TG4050 One patient, one cancer, one vaccine TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial.   TG4050 video  Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050,… Continue reading myvac-box

invirio-box

Oncolytic viruses A new generation of products These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.   Oncolytic viruses video

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits